Published in Cancer Discov on October 02, 2015
A Study of AMG 337 in Subjects With Advanced Solid Tumors | NCT01253707
Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers. Oncotarget (2016) 0.81
Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation. Oncotarget (2016) 0.77
Molecular predictive markers in tumors of the gastrointestinal tract. World J Gastrointest Oncol (2016) 0.75
Understanding the Precision in "Precision Medicine". Oncologist (2016) 0.75
EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma. J Gastrointest Oncol (2016) 0.75
Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy. Genome Med (2017) 0.75
Novel Targeted Therapies for Esophagogastric Cancer. Surg Oncol Clin N Am (2017) 0.75
Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification. Oncotarget (2017) 0.75
Update on Gastroesophageal Adenocarcinoma Targeted Therapies. Hematol Oncol Clin North Am (2017) 0.75
Targeted therapies for gastric cancer: failures and hopes from clinical trials. Oncotarget (2017) 0.75
Circulating Tumor DNA Identifies EGFR Co-Amplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. J Thorac Oncol (2017) 0.75
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nat Rev Clin Oncol (2017) 0.75
Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification. BMC Cancer (2017) 0.75
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A (2006) 5.23
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer (2006) 4.71
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol (2011) 3.27
The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev (2008) 2.41
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov (2011) 2.22
Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov (2014) 1.77
Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res (2011) 1.67
MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.42
Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br J Cancer (2011) 1.03
Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Invest (2014) 0.92
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discov (2015) 1.70
Dendritic Cells in Kidney Transplant Biopsy Samples Are Associated with T Cell Infiltration and Poor Allograft Survival. J Am Soc Nephrol (2015) 0.81
Health Care Infrastructure for Financially Sustainable Clinical Genomics. J Mol Diagn (2016) 0.76